Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Chimerix Inc (NQ: CMRX )

0.9726 +0.0220 (+2.31%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Chimerix Inc

Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Chimerix, Inc.
Via GlobeNewswire
Chimerix Strengthens Executive Leadership Team with Appointment of Thomas Riga as Chief Operating and Commercial Officer
Seasoned Executive Brings More Than 25 Years of Industry Leadership Experience in Oncology Commercialization and Corporate Business Development 
From Chimerix, Inc.
Via GlobeNewswire
Chimerix Reports Third Quarter 2023 Financial Results and Provides Operational Update
From Chimerix, Inc.
Via GlobeNewswire
Chimerix to Report Third Quarter 2023 Financial Results and Provide an Operational Update on November 2, 2023
From Chimerix, Inc.
Via GlobeNewswire
Chimerix to Participate in Upcoming Investor Conferences
From Chimerix, Inc.
Via GlobeNewswire
Chimerix Announces Data Highlighting Clinical Efficacy and Molecular Mechanisms of Response to ONC201 Treatment of H3 K27M-Mutant Diffuse Midline Gliomas Published in "Cancer Discovery"
From Chimerix, Inc.
Via GlobeNewswire
Chimerix Reports Second Quarter 2023 Financial Results and Provides Operational Update
From Chimerix, Inc.
Via GlobeNewswire
Chimerix to Report Second Quarter 2023 Financial Results and Provide an Operational Update on August 3, 2023
From Chimerix, Inc.
Via GlobeNewswire
Chimerix Announces Promotion of Michael T. Andriole to President and Chief Executive Officer
From Chimerix, Inc.
Via GlobeNewswire
Chimerix to Participate in Fireside Chat at Jefferies Global Healthcare Conference
From Chimerix, Inc.
Via GlobeNewswire
Chimerix to Participate in Cancer Moonshot Brain Cancers Forum on Glioblastoma (GBM) and Diffuse Intrinsic Pontine Glioma (DIPG) at White House
Forum Aim is to Share Progress and Spur Actions to Advance the Field 
From Chimerix, Inc.
Via GlobeNewswire
Chimerix Reports First Quarter 2023 Financial Results and Provides Operational Update
From Chimerix, Inc.
Via GlobeNewswire
Chimerix to Report First Quarter 2023 Financial Results and Provide an Operational Update on May 4, 2023
From Chimerix, Inc.
Via GlobeNewswire
Chimerix Announces Presentation of Multiple Imipridone Datasets at American Association for Cancer Research Annual Meeting
From Chimerix, Inc.
Via GlobeNewswire
Chimerix Reports Fourth Quarter and Year End 2022 Financial Results and Provides Operational Update
From Chimerix, Inc.
Via GlobeNewswire
Chimerix to Present at Cowen and Company 43rd Annual Health Care Conference
From Chimerix, Inc.
Via GlobeNewswire
Chimerix to Report Fourth Quarter and Year End 2022 Financial Results and Provide an Operational Update on March 2, 2023
From Chimerix, Inc.
Via GlobeNewswire
Chimerix to Present at 41st Annual J.P. Morgan Healthcare Conference
From Chimerix, Inc.
Via GlobeNewswire
Chimerix Announces Successful Launch of ONC201 Phase 3 ACTION Study at Society for Neuro-Oncology Conference and Provides Operational Update
From Chimerix, Inc.
Via GlobeNewswire
Chimerix Responds to Rubric Capital Management
Highlights Confidence in Ongoing Strategy and Future Clinical Development Plans 
From Chimerix, Inc.
Via GlobeNewswire
Rubric Capital Management Sends Letter to Chimerix Board of Directors
From Rubric Capital Management LP
Via Business Wire
Chimerix Reports Third Quarter 2022 Financial Results and Provides Operational Update
From Chimerix, Inc.
Via GlobeNewswire
Chimerix to Report Third Quarter 2022 Financial Results and Provide an Operational Update on November 3, 2022
From Chimerix, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.